Abiomed stock slips amid inquiry

Shares of heart pump maker Abiomed Inc. tumbled 4.3 percent Thursday after the Danvers company disclosed that its fourth-quarter sales were below expectations and it had received a federal subpoena relating to a civil investigation into its reimbursement practices.

In its earnings release, Abiomed said the subpoena from the Office of the Inspector General in the Boston regional office of the Department of Health and Human Services sought “materials relevant to the company’s reimbursement of expenses and remuneration to health care providers” during the second half of 2012. The company said it would comply with the request.


“We believe our physician reimbursement practices have been and currently are compliant with the industry standard,” said Abiomed spokeswoman Aimee Genzler.

Abiomed’s stock fell $1.03 a share, to $22.66, on the Nasdaq stock exchange.

Robert Weisman

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of